New pneumococcal 15-valent conjugate vaccine that includes coverage against serotype 3

Description

In this Product Explainer, Public Health Physician and Infectious Diseases Epidemiologist Prof Paul Van Buynder explains the burden of pneumococcal disease in both children and adult population. He explains why PCV 15 has increased serotype coverage and why improved immunogenicity against serotype 3 is important both from a clinical and public health perspective (5 mins).

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Prof Peter Wong

Prof Peter Wong

Fracture Prevention and Osteoporosis Management After Menopause

Dr Richard Symes

Dr Richard Symes

Ophthalmology Update: New Treatments for Old Conditions

Prof Bu Yeap

Prof Bu Yeap

Testosterone for Men – Common Myths and Recent Development

Dr Victoria Hayes

Dr Victoria Hayes

Conversation Strategies for Unfunded Vaccinations

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Prof Paul Van Buynder

expert

Prof Paul Van Buynder

Public Health Physician and Infectious Diseases Epidemiologist; Professor, School of Medicine, Griffith University, Queensland

Date published: 1 January 1970